O PIONEERs!

Circulation

Volumn 135, Issue 4, 2017, Pages 334-337

  Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Editorials

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RIVAROXABAN; WARFARIN;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL; CORONARY STENTING; DRUG ELUTING CORONARY STENT; DUAL ANTIPLATELET THERAPY; HOSPITALIZATION; HUMAN; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; REVIEW; STENT THROMBOSIS; COMBINATION DRUG THERAPY;

ANTICOAGULANTS; DRUG THERAPY, COMBINATION; PLATELET AGGREGATION INHIBITORS; WARFARIN;

EID: 84996956275     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.025923     Document Type: Review

References (15)

1. Bhatt DL, Hulot JS, Moliterno DJ, Harrington RA, Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res 2014 114 1929 1943. doi: 10.1161/CIRCRESAHA.114.302737
2. Bhatt DL, Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med 2007 357 2078 2081. doi: 10.1056/NEJMe0706859
3. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van 't Hof AW, ten Berg JM, WOEST study investigators Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013 381 1107 1115. doi: 10.1016/S0140-6736(12)62177-1
4. Fiedler KA, Maeng M, Mehilli J, Schulz-Schüpke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N, Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 2015 65 1619 1629. doi: 10.1016/j.jacc.2015.02.050
5. Bhatt DL, When is a double better than a triple?: stenting in patients with atrial fibrillation. J Am Coll Cardiol 2015 65 1630 1632. doi: 10.1016/j.jacc.2015.02.051
6. Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, Bode C, Halperin J, Verheugt FWA, Wildgoose P, Burton P, van Eickels M, Korjian S, Daaboul Y, Jain P, Lip GYH, Cohen M, Peterson ED, Fox KAA, Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-Adjusted oral vitamin k antagonist treatment strategy. Circulation 2017 135 323 333. doi: 10.1161/CIRCULATIONAHA.116.025783
7. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Szlosek D, Lip GY, Cohen M, Husted S, Peterson E, Fox K, An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-Adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention: PIONEER AF-PCI [published online ahead of print November 14, 2016]. N Engl J Med 2016. doi: 10.1056/NEJMoa1611594. http://www.nejm.org/search?q=doi%3A+10.1056%2FNEJMoa1611594. Accessed November 16, 2016
8. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H, Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011 123 2736 2747. doi: 10.1161/CIRCULATIONAHA.110.009449
9. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L, APPRAISE-2 Investigators Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011 365 699 708. doi: 10.1056/NEJMoa1105819
10. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM, ATLAS ACS 2-TIMI 51 Investigators Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012 366 9 19. doi: 10.1056/NEJMoa1112277
11. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gómez-Hospital JA, Baz JA, Martin-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW, Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012 380 1482 1490. doi: 10.1016/S0140-6736(12)61223-9
12. Bhatt DL, EXAMINATION of new drug-eluting stents-Top of the class! Lancet 2012 380 1453 1455. doi: 10.1016/S0140-6736(12)61021-6
13. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J, Short-And long-Term outcomes with drug-eluting and bare-metal coronary stents: a mixed-Treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012 125 2873 2891. doi: 10.1161/CIRCULATIONAHA.112.097014
14. Qamar A, Bhatt DL, Stroke prevention in atrial fibrillation in patients with chronic kidney disease. Circulation 2016 133 1512 1515. doi: 10.1161/CIRCULATIONAHA.115.018549
15. Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH, Design and rationale of the RE-DUAL PCI trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clin Cardiol 2016 39 555 564. doi: 10.1002/clc.22572